Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy

alexandrossfakianakis shared this article with you from Inoreader Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy via Journal of Human Genetics - Issue - nature.com science feeds Journal of Human Genetics, Published online: 13 June 2022; doi:10.1038/s10038-022-01055-8 Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Upper Airway Stimulation for Children With Down Syndrome and Obstructive Sleep Apnea

alexandrossfakianakis shared this article with you from Inoreader Upper Airway Stimulation for Children With Down Syndrome and Obstructive Sleep Apnea via JAMA Otolaryngology–Head & Neck Surgery Current Issue The treatment of persistent obstructive sleep apnea (OSA) after an adenotonsillectomy is a challenge, especially for children with Down syndrome. As otolaryngologists with sleep subcertification, we are keenly aware of the current limitations for both medical and secondary surgical treatment options for this cohort. We applaud the insight of Yu and colleagues for their landmark investigation in this issue of JAMA Otolaryngology–Head & Neck Surgery on upper airway stimulation (UAS) for adolescents with Down syndrome and OSA, which expan ds the role of UAS from adults to children. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss Meta-analysis

alexandrossfakianakis shared this article with you from Inoreader Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss Meta-analysis via JAMA Otolaryngology–Head & Neck Surgery Current Issue To the Editor We read with great interest the recent meta-analysis from Joshua et al, titled "Hyperbaric Oxygen Therapy [HBOT] for Patients with Sudden Sensorineural Hearing Loss [SSNHL]" and the commentary by Moody-Antonio et al. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A Middle-aged Woman With Parotid Swelling

alexandrossfakianakis shared this article with you from Inoreader A Middle-aged Woman With Parotid Swelling via JAMA Otolaryngology–Head & Neck Surgery Current Issue A 53-year-old woman with a history of coronary artery dise ase and prior myocardial infarction that was treated with warfarin presents to the emergency department after awakening with right preauricular and right upper neck swelling. What is your diagnosis? View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Tumor Grade and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma

alexandrossfakianakis shared this article with you from Inoreader Tumor Grade and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma via JAMA Otolaryngology–Head & Neck Surgery Current Issue This cohort study investigates the association between tu mor grade and immunotherapy response in patients with recurrent or metastatic head and neck squamous cell carcinoma. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Silent Sinus Syndrome Involving the Frontal Sinus

alexandrossfakianakis shared this article with you from Inoreader Silent Sinus Syndrome Involving the Frontal Sinus via JAMA Otolaryngology–Head & Neck Surgery Current Issue This case report describes a man in his 50s who presented with a 1-year history of a painless, progressive sunken appearance of his right eye and was subsequently diagnosed with right frontal silent sinus syndrome. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A phase 2 pharmacodynamic dose‐finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer

alexandrossfakianakis shared this article with you from Inoreader A phase 2 pharmacodynamic dose‐finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer via Pediatric Blood & Cancer Abstract Data from registrational trials of pediatric venous thromboembolism (VTE) treatment are sparse, especially among cancer patients. We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old. Among 38 patients (cancer, n = 26; noncancer, n = 12), median dalteparin dose requirements per kilogram varied with age but not cancer status. Risks of CRB and srVTE were <4% in cancer and noncancer subgroups. Dalteparin is an important FDA-approved treatment for pediatric VTE, particularly with cancer. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.